Dr. Shuobo (Shu) Boboila is an associate in the New York City office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her work focuses on patent prosecution and due diligence matters for clients in the life sciences and biotechnology industries. Shu’s technical expertise includes cellular and molecular biology, cancer therapy, genetics, and pharmacology.
Prior to joining the firm, Shu completed her doctoral and postdoctoral trainings at Columbia University, where she worked on immunotherapy and radiation therapy for treatment of pediatric tumors. She also interned at Columbia Technology Ventures, the technology transfer office for Columbia University.
Dr. Shuobo (Shu) Boboila is an associate in the New York City office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her work focuses on patent prosecution and due diligence matters for clients in the life sciences and biotechnology industries. Shu’s technical expertise includes cellular and molecular biology, cancer therapy, genetics, and pharmacology.
Prior to joining the firm, Shu completed her doctoral and postdoctoral trainings at Columbia University, where she worked on immunotherapy and radiation therapy for treatment of pediatric tumors. She also interned at Columbia Technology Ventures, the technology transfer office for Columbia University.
- J.D., Duke University School of Law, 2022
- Postdoctoral Fellowship, Radiation Oncology, Columbia University, 2019
- Ph.D., Pathology and Molecular Mechanisms of Diseases, Columbia University, 2015
- B.S., Biochemistry, University of Bristol, 2007
- State Bar of New York
- U.S. Patent and Trademark Office
- J.D., Duke University School of Law, 2022
- Postdoctoral Fellowship, Radiation Oncology, Columbia University, 2019
- Ph.D., Pathology and Molecular Mechanisms of Diseases, Columbia University, 2015
- B.S., Biochemistry, University of Bristol, 2007
- State Bar of New York
- U.S. Patent and Trademark Office
Select Publications
- Co-author, “Akt inhibition is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, Her2 receptor negative breast cancer,” 10 Frontiers in Oncology 968, 2020
- Co-author, “High-dose radiation increases Notch1 in tumor vasculature,” 106(4) Int J Radiat Oncol Phys. 857-866, 2019
- Co-author, “Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma,” 37(40) Oncogene 5451-5465, 2018
Select Publications
- Co-author, “Akt inhibition is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, Her2 receptor negative breast cancer,” 10 Frontiers in Oncology 968, 2020
- Co-author, “High-dose radiation increases Notch1 in tumor vasculature,” 106(4) Int J Radiat Oncol Phys. 857-866, 2019
- Co-author, “Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma,” 37(40) Oncogene 5451-5465, 2018
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell therapy
- Cellular biology
- Cellular immunology
- Immuno-oncology
- Immunobiology
- Immunology
- T and B cell biology
- T cell biology
- T cell immunology
Therapeutics and Drug Discovery
- Drug delivery
- Gene therapy
- Immunotherapy targets
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell therapy
- Cellular biology
- Cellular immunology
- Immuno-oncology
- Immunobiology
- Immunology
- T and B cell biology
- T cell biology
- T cell immunology
Therapeutics and Drug Discovery
- Drug delivery
- Gene therapy
- Immunotherapy targets
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
- Privacy Policy
- Terms of Use
- Accessibility